Can Darling Ingredients Turn Collagen Into a Bigger Earnings Engine?

Darling Ingredients is shifting its Food segment toward collagen, which delivers roughly 2.5-3.0x gelatin margins, while targeted ingredients generate 7-11x gelatin margins using existing Rousselot facilities. Collagen's Food-segment EBITDA contribution rose from 35% in 2020 to 48% in 2025 and is projected to reach 50% by 2030, supporting margin and cash-flow improvement. DAR shares have gained 20.5% over three months and trade at a 10.07x forward P/E, below the industry’s 14.56x and the consumer-staples sector’s 17.06x.

Analysis

The market is likely to underwrite DAR primarily as a renewable-fuels/animal-rendering earnings proxy, so a sustained Food-margin upgrade could reduce the multiple discount only if management begins separately disclosing collagen revenue, price/mix, and incremental EBITDA. The key mechanism is operating leverage from repurposing existing capacity: mix-led gross-margin expansion should require materially less capital than volume growth, improving free-cash-flow conversion and making Food earnings less correlated with renewable-diesel margins. This is a potentially valuable diversification, but it is unlikely to move consolidated estimates meaningfully in the next quarter without quantified segment guidance.

The near-term risk is that collagen demand is not as insulated from consumer-health inventory cycles as the narrative implies; Asia distributor destocking, weaker premium supplement demand, or lower whey prices could narrow the substitution advantage. A second-order constraint is raw-material availability: stronger collagen mix raises the value of selected bovine/porcine inputs and may increase competition for high-grade feedstock, limiting gross-margin capture unless DAR's procurement network retains its historical advantage. The contrarian view is that the recent share move may already reflect a recovery narrative while the more material earnings swing remains renewable diesel and low-carbon fuel-credit economics; Food deserves a rerating only after margin expansion is demonstrated rather than projected.

Over 6-18 months, DAR's scale and installed processing base could create a defensible advantage versus smaller specialty-ingredient producers, which generally need customer qualification, formulation support, and dedicated capacity to compete. The relevant catalyst path is 1-3 months: next earnings should reveal whether Food EBITDA growth is mix-driven despite flat-to-modest volumes, followed by contract wins in nutrition and health applications. Thesis falsification would be Food EBITDA margin stagnation for two reporting periods, incremental capex rising disproportionately to mix gains, or a renewed deterioration in renewable-diesel profitability overwhelming the segment benefit.

Key Decisions for Investors

• Initiate a modest long DAR only on confirmation that Food-segment EBITDA margin expands sequentially while capital expenditure remains contained; target a 6-12 month rerating toward specialty-ingredients multiples, but size as a satellite position because fuel-credit exposure can dominate consolidated earnings.
• Use the next earnings release as the entry catalyst: add if management quantifies collagen/targeted-ingredient growth and raises Food profitability expectations; avoid chasing if results rely on volume growth without disclosed price/mix or margin improvement.
• Pair long DAR against short XLE or a renewable-fuels proxy only after verifying that Food EBITDA is becoming a larger share of cash generation; this isolates the proposed specialty-ingredients rerating, but the trade is premature without segment-level evidence.
• Set a thesis stop on two consecutive quarters of flat/down Food EBITDA margin or guidance indicating meaningful new capacity spending. Those outcomes would imply that higher-value mix is being competed away or is less capital-light than assumed.